Literature DB >> 9747459

Superiority of the ear pinna over muscle tissue as site for DNA vaccination.

P Förg1, P von Hoegen, W Dalemans, V Schirrmacher.   

Abstract

Three different vaccination sites were compared for efficiency of immunization with naked DNA. Using the bacterial lacZ gene as a model, all three sites of the mouse (skeletal muscle, dermis of abdominal skin or of the ear pinna) could express the gene product beta-gal but varied in expression time with muscle tissue showing the longest expression. Expression time, however, did not correlate with immune response intensity. The ear pinna was by far the most effective and muscle the least effective priming site for specific humoral and cytotoxic T cell-mediated immune responses. Following intra-pinna DNA inoculation, beta-gal expressing cells were detectable around the injection site and in the major draining lymph node. Efficiency of immunization was also dependent on the promoter and expression vector used. The cytomegalus virus promoter driven pCMV beta vector was superior to the Moloney murine leukemia virus LTR driven BAG vector. LacZ DNA immunization was also compared with cell-based vaccination with lacZ-transfected tumor cells, in which case again the pinna was the best site for inducing strong immune responses. Tumor-specific T cell responses could also be well induced in the pinna, leading to cytotoxic T lymphocyte induction and protective antitumor immunity. Thus, the pinna was found to be a privileged site for induction of antitumor responses and for genetic immunization, an important finding of immediate practical and potential future clinical implications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9747459     DOI: 10.1038/sj.gt.3300628

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Effect of tape stripping and adjuvants on immune response after intradermal DNA electroporation.

Authors:  Gaëlle Vandermeulen; Liévin Daugimont; Hervé Richiardi; Marie-Lise Vanderhaeghen; Nathalie Lecouturier; Bernard Ucakar; Véronique Préat
Journal:  Pharm Res       Date:  2009-04-21       Impact factor: 4.200

3.  DNA Vaccine Targeting Gonadotropin-Releasing Hormone Receptor and Its Application in Animal Contraception.

Authors:  Alexandre Samoylov; India Napier; Nancy Morrison; Anna Cochran; Bettina Schemera; James Wright; Russell Cattley; Tatiana Samoylova
Journal:  Mol Biotechnol       Date:  2019-02       Impact factor: 2.695

4.  A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein.

Authors:  Emma Herrera; Patricia Barcenas; Rubicela Hernández; Alfonso Méndez; Guillermo Pérez-Ishiwara; Blanca Barrón
Journal:  Virol J       Date:  2010-08-20       Impact factor: 4.099

5.  Neutrophils are dispensable in the modulation of T cell immunity against cutaneous HSV-1 infection.

Authors:  Jyh Liang Hor; William R Heath; Scott N Mueller
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

6.  A detailed characterisation of the distribution and presentation of DNA vaccine encoded antigen.

Authors:  Catherine M Rush; Timothy J Mitchell; Paul Garside
Journal:  Vaccine       Date:  2009-12-23       Impact factor: 3.641

7.  Toll-Like Receptor 9 Activation Rescues Impaired Antibody Response in Needle-free Intradermal DNA Vaccination.

Authors:  Prabhu S Arunachalam; Ria Mishra; Krithika Badarinath; Deepak Selvam; Sravan K Payeli; Richard R Stout; Udaykumar Ranga
Journal:  Sci Rep       Date:  2016-09-23       Impact factor: 4.379

Review 8.  Less Can Be More: The Hormesis Theory of Stress Adaptation in the Global Biosphere and Its Implications.

Authors:  Volker Schirrmacher
Journal:  Biomedicines       Date:  2021-03-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.